Geneva, Switzerland (PRWEB) December 17, 2013
Selexis SA, a serial innovation company focused on drug discovery for lead identification and cell line development for scale-up and manufacturing of therapeutic protein drugs announced today data from the Company’s SURE CHO-Mplus™ Libraries will be presented at the 13th Annual PepTalk Conference, January 13-17, 2014 at the Renaissance Hotel & Palm Springs Convention Center in Palm Springs, California.
Selexis’ CSO, Pierre-Alain Girod, Ph.D., will present, “Selexis SURE CHO-Mplus™ Libraries: Custom Solutions for Protein Expression Bottlenecks,” on Wednesday, January 15 at 12:15 PM as part of the Pipeline 5 Recombinant Protein Expression and Production - ‘Improving Yields’ tract.
Ideal protein expression systems should both boost transcription as well as address expression bottlenecks. For the newest SUREtechnology innovation, Selexis leveraged data from the completed SURE CHO-M Genome and Transcriptome project to engineer the SURE CHO-Mplus Libraries designed to address expression issues in CHO-M cells. Selexis’ expression technology doesn’t need antibiotic selection, allowing for screening of multiple auxillary proteins simultaneously. These libraries boost expression over broad range of difficult-to-express proteins.
Dr. Girod and the Company’s director of business development, Dr. Marco Bocci, will be available for questions at Selexis booth 307 from January 13 - 17. Please see conference website for complete schedule.
About Selexis SA
Headquartered in Geneva, Switzerland, Selexis SA is a global life science company with innovative technologies and world-class expert services for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins. The Company’s SUREtechnology Platform™ is based on Selexis Genetic Elements™ — novel DNA-based elements that control the dynamic organization of chromatin within all mammalian cells and allow for higher and more stable expression of recombinant proteins. Selexis has generated cell lines being used in a variety of programs from drug discovery to late-stage clinical trials.
For more information: